Focal Interest
Focal Interest

Nivolumab

  1. Combination therapy showed a temporary response in metastatic DDCS
    Case report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.